Michael Burkes Brophy Sells 782 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 782 shares of Natera stock in a transaction on Monday, July 27th. The shares were sold at an average price of $260.49, for a total value of $203,703.18. Following the sale, the chief financial officer directly owned 56,714 shares of the company’s stock, valued at approximately $14,773,429.86. The trade was a 1.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, July 29th, Michael Burkes Brophy sold 1,863 shares of Natera stock. The stock was sold at an average price of $249.38, for a total value of $464,594.94.
• On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The stock was sold at an average price of $253.96, for a total value of $614,329.24.
• On Monday, May 4th, Michael Burkes Brophy sold 482 shares of Natera stock. The shares were sold at an average price of $210.49, for a total value of $101,456.18.
• On Friday, May 1st, Michael Burkes Brophy sold 313 shares of Natera stock. The shares were sold at an average price of $206.16, for a total value of $64,528.08.

Natera Stock Performance

NASDAQ:NTRA opened at $269.66 on Friday. The stock’s 50 day moving average price is $245.48 and its 200 day moving average price is $221.90. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04. The company has a market capitalization of $38.62 billion, a P/E ratio of -165.44 and a beta of 1.51.

Analyst Ratings Changes

Several research analysts have recently commented on NTRA shares. Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 price objective on shares of Natera in a research note on Tuesday, May 12th. Wells Fargo & Company upped their price objective on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Wolfe Research started coverage on shares of Natera in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 target price on the stock. Finally, Sanford C. Bernstein began coverage on Natera in a report on Friday, June 26th. They set an “outperform” rating and a $310.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $267.83.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Analyst sentiment remains favorable: Canaccord Genuity raised its price target to $330 and maintained a “buy” rating, while the broader analyst consensus is “Moderate Buy” with an average target of $267.83. Analyst and Natera market coverage
• Positive Sentiment: Institutional ownership and recent buying provide additional support. Major investors including Coatue Management, Wellington Management, Norges Bank, JPMorgan and AQR Capital Management increased their positions; institutions collectively own approximately 99.9% of the stock.
• Neutral Sentiment: CFO Michael Burkes Brophy sold 5,064 shares worth about $1.28 million, while CEO Steven Leonard Chapman sold 5,770 shares for roughly $1.48 million. Because the sales were pre-arranged and intended to satisfy tax-withholding obligations, they are less likely to signal reduced management confidence. CFO SEC filing CEO SEC filing
• Neutral Sentiment: Insiders John Fesko and Solomon Moshkevich also sold shares under similar tax-related plans, while retaining sizable positions. Fesko’s latest sale involved 782 shares worth approximately $203,700. Fesko SEC filing
• Negative Sentiment: The concentration of insider selling could create modest short-term selling pressure and may prompt valuation concerns. Natera also trades at a high valuation relative to its earnings profile, with a negative trailing price-to-earnings ratio, although no new operational warning accompanied the filings.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Integrated Wealth Concepts LLC grew its position in shares of Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC boosted its stake in Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after purchasing an additional 1,847 shares during the period. Focus Partners Wealth grew its holdings in Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after buying an additional 474 shares during the last quarter. Sivia Capital Partners LLC bought a new position in Natera in the 2nd quarter worth approximately $298,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Natera in the second quarter valued at approximately $558,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.